Trials involving Multiple Types of Cancer

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Merck) MK-3475-587 / KEYNOTE 587A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab TrialMcWhirter, Dr ElaineOpen to recruitmentNCT03486873
(CCTG) IND.238A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related ToxicityEllis, Dr PeterOpen to recruitmentNCT03847649
(HHS) CRUSSHStereotactic body radiotherapy (SBRT) boost following urgent 3D conformal radiotherapy in the treatment of metastatic epidural spinal cord compression (SCC): A phase I feasibility trialSchnarr, Dr KaraOpen to recruitmentNCT03529708
(IMV) Immunovac / P1719-SUR-Z11A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid TumoursHirte, Dr HalOpen to recruitmentNCT03836352
(Merck) MK-7902-005-00 / LEAP-005 / E7080-G000-224A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)Hotte, Dr SebastienOpen to recruitmentNCT03797326
(BMS) CA021002A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid TumorsHotte, Dr SebastienOpen to recruitmentNCT03251924
(Tesaro) 4010-01-001 / GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1
Monoclonal Antibody, in Patients with Advanced Solid Tumors
Elit, Dr LaurieOpen to recruitmentNCT02715284
(Ayala) AL-ACC-01 / ACCURACYA Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch MutationsHotte, Dr SebastienOpen to recruitmentNCT03691207
(Debio) 1143-NSCLC-105A phase-Ib dose-finding study of the SMAC mimetic Debio 1143 when given in combination with the anti-PD-L1 antibody avelumab to patients with advanced solid malignancies and, in an expansion cohort, to patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after platinum-based therapyJuergens, Dr RosalynOpen to recruitmentNCT03270176
(UHN) OCTANEOntario-wide Cancer TArgeted Nucleic acid Evaluation (OCTANE)Hotte, Dr SebastienSuspended/On holdNCT02906943
(AstraZeneca) D4191C00068 / STRONGAn Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) – Core Protocol; Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary TractHotte, Dr SebastienSuspended/On holdNCT03084471
Download PDF